China's drug safety agency has approved the sale of the new Alzheimer's drug, called Oligomannate, which uses seaweed to treat mild to moderate forms of the cognitive disorder.Original Article
China OKs Seaweed-Based Alzheimer’s Treatment
You may also like
Ninth Circuit Upholds FDA’s Authority to Regulate...
Skinny-Label Lives to See Another Day
Bring Out Your Meds! Bring Out Your Meds!
Homeopathic Industry Group Wants Court to Exclude It...
A Reversal on Sequencing? Proposed Legislation Would...
FDA Guidance Outlines a Framework for the Evaluation...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.